骨肉瘤(Osteosarcoma)是起源于骨骼的恶性肿瘤,好发于青少年的长骨干骺端,最多见于膝关节周围,发病率约为2～3例/106。其恶性程度高,不仅局部侵袭性强,而且易于发生转移。最近30年,常规骨肉瘤的治疗如新辅助化疗、保肢手术都取得了很大的进展,骨肉瘤的5年生存率可达到60%～80%,但仍有病人因肿瘤复发、转移而导致治疗失败,人们针对骨肉瘤及其肺转移已探索开展了免疫基因治疗、反义基因治疗、抑癌基因治疗、自杀基因靶向治疗等多种极富前景的肿瘤基因治疗方法。经过科学工作者多年的努力,骨肉瘤的治疗已经达到了一个全新的水平。本文将对骨 Osteosarcoma (Osteosarcoma) is a malignant tumor originating in bone. It occurs in the metaphysis of the long bones of young people, most often around the knee joint. The incidence rate is about 2 to 3 cases / 106. Its high degree of malignancy, not only locally invasive, but also prone to metastasis. In recent 30 years, the treatment of conventional osteosarcoma such as neoadjuvant chemotherapy and limb salvage surgery have made great progress. The 5-year survival rate of osteosarcoma can reach 60% to 80%, but there are still patients with tumor recurrence and metastasis Leading to failure of treatment, osteosarcoma and its lung metastases have been explored for many promising gene therapy methods such as immunotherapy, antisense gene therapy, tumor suppressor gene therapy and suicide gene therapy. After many years of scientific workers efforts, the treatment of osteosarcoma has reached a whole new level. This article will be on the bone